- Home
- STTK vs SABR Comparison
STTK vs SABR Comparison
Compare STTK & SABR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STTK | SABR |
|---|---|---|
| Founded | 2016 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 569.1M | 580.9M |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | STTK | SABR |
|---|---|---|
| Price | $7.03 | $1.86 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 7 | 1 |
| Target Price | ★ $10.00 | $1.50 |
| AVG Volume (30 Days) | 424.3K | ★ 3.7M |
| Earning Date | 05-01-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 53.02 | ★ 283.56 |
| EPS | N/A | ★ 1.34 |
| Revenue | $1,000,000.00 | ★ $3,866,956,000.00 |
| Revenue This Year | N/A | $7.51 |
| Revenue Next Year | N/A | $3.46 |
| P/E Ratio | ★ N/A | $1.36 |
| Revenue Growth | N/A | ★ 7.46 |
| 52 Week Low | $0.71 | $0.81 |
| 52 Week High | $8.33 | $3.46 |
Technical Indicators
Market Signals| Indicator | STTK | SABR |
|---|---|---|
| Relative Strength Index (RSI) | 49.99 | 60.89 |
| Support Level | $5.75 | $1.72 |
| Resistance Level | $7.68 | $1.99 |
| Average True Range (ATR) | 0.52 | 0.12 |
| MACD | -0.13 | -0.00 |
| Stochastic Oscillator | 17.27 | 68.48 |
Price Performance
Historical ComparisonAbout STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About SABR Sabre Corporation
Sabre holds the number-two air booking volume share in the global distribution system industry. The distribution segment represented 80% of total 2025 revenue and airline IT solutions 20% of revenue. The company sold its growing hotel IT solutions division to TPG in 2025 for $960 million in net proceeds. Transaction fees, which are mostly tied to volume and not price, account for the bulk of sales and profits.